Luteolin and abyssinone II as potential inhibitors of SARS-CoV-2: an in silico molecular modeling approach in battling the COVID-19 outbreak

[1]  Gideon Adamu Shallangwa,et al.  Docking-based strategy to design novel flavone-based arylamides as potent V600E-BRAF inhibitors with prediction of their drug-likeness and ADMET properties , 2020 .

[2]  A. Gurung,et al.  Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 Mpro enzyme through in silico approach , 2020, Life Sciences.

[3]  Y. Uno.  Camostat mesilate therapy for COVID-19 , 2020, Internal and Emergency Medicine.

[4]  Zongyang Lv,et al.  Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design , 2020, bioRxiv.

[5]  Eric A. Meyerowitz,et al.  Rethinking the role of hydroxychloroquine in the treatment of COVID‐19 , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  S. Olsen,et al.  Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design , 2020 .

[7]  Jerrine Joseph,et al.  Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach , 2020, Journal of biomolecular structure & dynamics.

[8]  Kemal Yelekçi,et al.  Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes , 2020, Journal of biomolecular structure & dynamics.

[9]  M. Mazer-Amirshahi,et al.  Pharmacotherapy in COVID-19; A narrative review for emergency providers , 2020, The American Journal of Emergency Medicine.

[10]  P. Davoodian,et al.  Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study , 2020, Journal of biomolecular structure & dynamics.

[11]  Bhumi M. Shah,et al.  In silico studies on therapeutic agents for COVID-19: Drug repurposing approach , 2020, Life Sciences.

[12]  S. Chandra,et al.  In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking. , 2020, European review for medical and pharmacological sciences.

[13]  D. Wang,et al.  The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status , 2020, Military Medical Research.

[14]  Cynthia Liu,et al.  Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases , 2020, ACS central science.

[15]  D. Raoult,et al.  New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? , 2020, International Journal of Antimicrobial Agents.

[16]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[17]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[18]  S. Asgary,et al.  The Signaling Pathways, and Therapeutic Targets of Antiviral Agents: Focusing on the Antiviral Approaches and Clinical Perspectives of Anthocyanins in the Management of Viral Diseases , 2019, Front. Pharmacol..

[19]  J. Amani,et al.  Designing a multi-epitope vaccine for cross-protection against Shigella spp: An immunoinformatics and structural vaccinology study. , 2019, Molecular immunology.

[20]  Y. Blume,et al.  Protein phosphatases potentially associated with regulation of microtubules, their spatial structure reconstruction and analysis , 2019, Cell biology international.

[21]  Olivier Michielin,et al.  SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules , 2019, Nucleic Acids Res..

[22]  Hongbin Yang,et al.  ADMET-score - a comprehensive scoring function for evaluation of chemical drug-likeness. , 2019, MedChemComm.

[23]  Waqar Hussain,et al.  Computational exploration of antiviral activity of phytochemicals against NS2B/NS3 proteases from dengue virus , 2018, Turkish Journal of Biochemistry.

[24]  David Ramírez,et al.  Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data? , 2018, Molecules.

[25]  K. Zandi,et al.  Flavonoids: promising natural compounds against viral infections , 2017, Archives of Virology.

[26]  Mohammad Tuhin Ali,et al.  Halogen-directed drug design for Alzheimer’s disease: a combined density functional and molecular docking study , 2016, SpringerPlus.

[27]  R. Hilgenfeld.  From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design , 2014, The FEBS journal.

[28]  Marcus D. Hanwell,et al.  Avogadro: an advanced semantic chemical editor, visualization, and analysis platform , 2012, Journal of Cheminformatics.

[29]  Olivier Michielin,et al.  Defining and searching for structural motifs using DeepView/Swiss-PdbViewer , 2012, BMC Bioinformatics.

[30]  M. Mezei,et al.  Molecular docking: a powerful approach for structure-based drug discovery. , 2011, Current computer-aided drug design.

[31]  S. Riazuddin,et al.  Antiviral activity of Acacia nilotica against Hepatitis C Virus in liver infected cells , 2011, Virology Journal.

[32]  Shibo Jiang,et al.  The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.

[33]  R. Sanchez,et al.  Improving accuracy and efficiency of blind protein‐ligand docking by focusing on predicted binding sites , 2009, Proteins.

[34]  Taehoon Kim,et al.  CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..

[35]  S. Lee,et al.  Phytochemicals: the good, the bad and the ugly? , 2007, Phytochemistry.

[36]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.

[37]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[38]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[39]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[40]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[41]  G. Hannon,et al.  Crystal Structure of Argonaute and Its Implications for RISC Slicer Activity , 2004, Science.

[42]  Ola Snøve,et al.  Many commonly used siRNAs risk off-target activity. , 2004, Biochemical and biophysical research communications.

[43]  Saurabh Menon,et al.  ACE2 X-Ray Structures Reveal a Large Hinge-bending Motion Important for Inhibitor Binding and Catalysis , 2004, Journal of Biological Chemistry.

[44]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[45]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[46]  J. Luban.  SARS-CoV-2 , 2020 .

[47]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..